Arovella Therapeutics Ltd has released a press release.
ZolpiMist Launch Australia
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Story so far
Earlier from Arovella Therapeutics
- Adopts WEF Framework For ESG Reporting
- Services Agreement with Q-Gen for CAR19-iNKT manufacture
- Anagrelide patent for the United States
- Arovella Therapeutics: Proposed issue of securities - ALA
- Application for quotation of securities - ALA
Later from Arovella Therapeutics
- Sumatriptan Update
- Quarterly Appendix 4C and Activities Report
- Preliminary Final Report
- Preclinical trial of ALA iNKT therapy and IMU onCARlytics
- Arovella to close its Perth OroMist R&D Facility
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics